Medtronic plc (MDT)
Brokers Suggest Investing in Medtronic (MDT): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Is This the Right Time to Hold Medtronic Stock in Your Portfolio?
MDT's Cardiovascular gains and renal denervation growth offer upside, but tariffs and currency headwinds cloud its outlook.
Medtronic (MDT) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Insights Into Medtronic (MDT) Q1: Wall Street Projections for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2026.
MDT's Q1 Earnings on Deck: How Should You Play the Stock Now?
Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.
Medtronic (MDT) Stock Dips While Market Gains: Key Facts
In the latest trading session, Medtronic (MDT) closed at $91.22, marking a -1.81% move from the previous day.
Medtronic: The CAS Catalyst Can Close A 27% Peer Discount
Medtronic is rated a 'Buy,' favored for its attractive valuation and potential upside from its CAS segment despite recent underperformance. CAS, now 5-6% of revenue, is annualizing above $2B and could reach $3B in a few years if execution remains strong. Guidance targets 6.75%-7.25% organic growth and $5.90-$6.00 EPS, but calendar effects and MiniMed separation timing are key variables.
Medtronic: Expecting Strong Revenue Growth In Fiscal Q1
Medtronic is reiterated as a "Buy," with shares offering over 10% fundamental upside and attractive valuation metrics. Q4 delivered 6.6% organic revenue growth—best in a decade—driven by double-digit gains in the Cardiovascular and Diabetes segments. FY 2027 guidance targets 6.75%-7.25% organic revenue growth and $5.90-$6.00 non-GAAP EPS, despite tariff and competitive headwinds.
Medtronic (MDT) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Medtronic (MDT) closed at $92.09, indicating a +1.64% shift from the previous trading day.
MDT vs. A: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or Agilent Technologies (A). But which of these two stocks presents investors with the better value opportunity right now?
Wall Street Bulls Look Optimistic About Medtronic (MDT): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know
In the closing of the recent trading day, Medtronic (MDT) stood at $89.41, denoting a +2.58% move from the preceding trading day.
